Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine PK and Genomic Variation in Breast Cancer
NCT00960544Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Planned start Jan 2019; status: withdrawn.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00960544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00960544.